Prognosis and Long-Term Health
At a Glance
After Anti-GBM disease, kidney recovery may take weeks or months and depends on kidney function at diagnosis and biopsy damage. If recovery does not occur, dialysis and transplant remain options; transplant is usually considered after remission and at least six months of undetectable antibodies.
The journey following an Anti-GBM diagnosis is often divided into two phases: the acute “storm” of intensive treatment and the long-term management of your health. While the initial goal is to save your life and preserve organ function, the long-term focus shifts to stabilizing your kidney function, managing any chronic damage, and monitoring for signs of relapse [1][2].
Predicting Kidney Recovery
One of the most profound questions after diagnosis is whether the kidneys will regain their ability to filter blood. It is important to know that recovery can sometimes take weeks or months; therefore, End-Stage Kidney Disease (ESKD) is not usually declared immediately after presentation, even if you temporarily need acute dialysis [3]. Your medical team will look at several factors to estimate your prognosis:
- Dialysis Status at Presentation: Studies indicate that patients who do not require dialysis when they are first diagnosed have a much higher likelihood of preserving long-term kidney function [3]. For patients who arrive at the hospital already requiring dialysis, the chance of recovering enough function to stop dialysis is lower, though certainly not impossible [3][4].
- Biopsy Findings: The amount of permanent damage seen on your biopsy provides critical clues. A higher proportion of “normal” (unaffected) glomeruli is associated with better chances of recovery [3][5]. Conversely, if nearly 100% of the filters show severe “crescents” or if there is extensive chronic scarring (Interstitial Fibrosis/Tubular Atrophy or IFTA), the likelihood of regaining independent kidney function is very low [5][6].
- No single percentage or rule guarantees a specific outcome. Your nephrologist will interpret these observational findings in the context of your unique case.
Life After the Acute Phase
If your kidneys do not recover, you will transition to long-term End-Stage Kidney Disease (ESKD) management, which involves chronic hemodialysis or peritoneal dialysis.
Regardless of your kidney function, monitoring for a return of the disease (relapse) is a key part of long-term care:
- For classic Anti-GBM disease, relapse is uncommon. While new symptoms should always be evaluated promptly, routine maintenance immunosuppression is generally not required once the initial disease is fully treated [7][8].
- If you are double-positive (testing positive for both anti-GBM and ANCA antibodies), your risk of relapse is notably higher. Your long-term care will follow protocols for ANCA-associated vasculitis, which may include years of “maintenance” medication and closer monitoring of your urine and blood [9][7].
Looking Toward Kidney Transplant
For patients whose kidneys have been permanently scarred, a kidney transplant offers an excellent long-term solution. Patients with Anti-GBM disease tend to have very successful transplant outcomes, with survival rates comparable to those who receive transplants for other conditions [10][11].
The Transplant Timeline
You cannot safely receive a new kidney while the disease is still active. Most transplant centers follow these guidelines:
- Clinical Remission: Your overall health must be stable, and the initial autoimmune attack must be completely resolved, with infections well controlled [12].
- Undetectable Antibodies: Generally, you must wait until the anti-GBM antibodies have been permanently undetectable in your blood for at least six months [12][13].
The risk of Anti-GBM disease attacking a new transplanted kidney is generally estimated to be very low (less than 2% in some observational cohorts), especially when strict waiting periods for antibody clearance are observed [14].
Long-Term Health Priorities
Whether you are recovering kidney function, managing dialysis, or preparing for a transplant, your long-term health plan requires a collaborative approach with your team:
- Blood Pressure and Fluid Management: Follow the specific, individualized blood pressure targets and fluid intake limits set by your nephrology team to ensure adequate blood flow without overloading your system.
- Routine Lab Work: Regular urinalysis (checking for blood or protein) and blood tests (monitoring creatinine and eGFR) are essential to catch any early signs of kidney strain or rare relapses [15]. Note that some blood or protein in the urine can persist simply from the prior injury, which is why your doctor monitors the trends.
- Medication Management: Work with your team on a safe schedule for tapering steroids, protecting your bone and stomach health, and maintaining your dialysis access points.
While the diagnosis of Anti-GBM disease is life-altering and intense, many patients successfully navigate the acute crisis and find stability through specialized care, vigilant monitoring, and the possibility of a transplant [10][2].
Common questions in this guide
Can my kidneys recover after I start dialysis for Anti-GBM disease?
What biopsy findings affect kidney recovery in Anti-GBM disease?
Does double-positive Anti-GBM and ANCA disease have a higher relapse risk?
When can I have a kidney transplant after Anti-GBM disease?
What follow-up care is needed after the acute phase of Anti-GBM disease?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Based on my biopsy and response to treatment, what is your assessment of my likelihood of coming off dialysis, recognizing that this can evolve over time?
- 2.Am I considered 'double-positive' for both anti-GBM and ANCA antibodies, and how will that specifically change my monitoring over the next few years?
- 3.What specific individualized target should we aim for regarding my blood pressure and fluid intake?
- 4.If my kidneys do not recover, what is this hospital’s specific protocol and timeline for referring me to a transplant center?
- 5.How often will we test my blood for antibodies now that the initial intensive treatment is over, and what other labs (like urine protein) will we watch?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
References
References (15)
- 1
Plasmapheresis, immunosuppressive therapy and anti-GBM disease prognosis: a cohort study of 107 patients.
Liu Y, Wu Y, Wei W, et al.
Renal failure 2024; (46(2)):2400539 doi:10.1080/0886022X.2024.2400539.
PMID: 39258391 - 2
Anti-glomerular basement membrane disease: A contemporary case series from a large university hospital center.
Catarina Oliveira A, Figueiredo R, Correia R, et al.
Nefrologia 2026; (46(7)):501522 doi:10.1016/j.nefroe.2026.501522.
PMID: 42618193 - 3
Risk Stratification to Predict Renal Survival in Anti-Glomerular Basement Membrane Disease.
Floyd L, Bate S, Hadi Kafagi A, et al.
Journal of the American Society of Nephrology : JASN 2023; (34(3)):505-514 doi:10.1681/ASN.2022050581.
PMID: 36446430 - 4
Predictors of renal and patient outcomes in anti-GBM disease: clinicopathologic analysis of a two-centre cohort.
Alchi B, Griffiths M, Sivalingam M, et al.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2015; (30(5)):814-21 doi:10.1093/ndt/gfu399.
PMID: 25609740 - 5
Predicting Outcome in Patients with Anti-GBM Glomerulonephritis.
van Daalen EE, Jennette JC, McAdoo SP, et al.
Clinical journal of the American Society of Nephrology : CJASN 2018; (13(1)):63-72 doi:10.2215/CJN.04290417.
PMID: 29162595 - 6
Anti-glomerular Basement Membrane Glomerulonephritis: A Study in Real Life.
Sánchez-Agesta M, Rabasco C, Soler MJ, et al.
Frontiers in medicine 2022; (9()):889185 doi:10.3389/fmed.2022.889185.
PMID: 35865174 - 7
Patients double-seropositive for ANCA and anti-GBM antibodies have varied renal survival, frequency of relapse, and outcomes compared to single-seropositive patients.
McAdoo SP, Tanna A, Hrušková Z, et al.
Kidney international 2017; (92(3)):693-702 doi:10.1016/j.kint.2017.03.014.
PMID: 28506760 - 8
Anti-glomerular basement membrane disease-treatment standard.
McAdoo SP, Pusey CD
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2025; (41(1)):42-54 doi:10.1093/ndt/gfaf190.
PMID: 40973182 - 9
Recurrent Nephritis and/or Pulmonary Hemorrhage in Patients with Anti-Glomerular Basement Membrane Disease with and without ANCA Positivity.
Droz N, Katz A, Patel A, et al.
Glomerular diseases 2021; (1(2)):60-67 doi:10.1159/000515388.
PMID: 36751425 - 10
Outcomes After Kidney Transplantation in Antiglomerular Basement Membrane Disease.
Traversat P, Dekervel M, Masset C, et al.
Kidney international reports 2025; (10(9)):3150-3163 doi:10.1016/j.ekir.2025.06.021.
PMID: 40980652 - 11
Long-term outcomes in kidney transplant recipients with end-stage kidney disease due to anti-glomerular basement membrane disease.
Singh T, Kharadjian TB, Astor BC, Panzer SE
Clinical transplantation 2021; (35(2)):e14179 doi:10.1111/ctr.14179.
PMID: 33259076 - 12
Recurrence of Goodpasture syndrome without circulating anti-glomerular basement membrane antibodies after kidney transplant, a case report.
Thibaud V, Rioux-Leclercq N, Vigneau C, Morice S
BMC nephrology 2019; (20(1)):6 doi:10.1186/s12882-018-1197-6.
PMID: 30621605 - 13
Kidney Transplantation After Rituximab Treatment for End-Stage Renal Failure With Myeloperoxidase Anti-neutrophil Cytoplasmic and Anti-glomerular Basement Membrane Antibody Positivity: A Case Report.
Sugiura T, Tanaka A, Nishibori N, et al.
Cureus 2025; (17(10)):e94237 doi:10.7759/cureus.94237.
PMID: 41209892 - 14
Recurrence and Outcome of Anti-Glomerular Basement Membrane Glomerulonephritis After Kidney Transplantation.
Coche S, Sprangers B, Van Laecke S, et al.
Kidney international reports 2021; (6(7)):1888-1894 doi:10.1016/j.ekir.2021.04.011.
PMID: 34307983 - 15
Late post-transplant recurrence of an anti-myeloperoxydase antibody-associated vasculitis in a former double-positive patient: a case report.
Chenaf-Benabdelmoumene N, Chabannes M, Ducloux D, et al.
Frontiers in immunology 2026; (17()):1723903 doi:10.3389/fimmu.2026.1723903.
PMID: 41716381
This page explains prognosis and long-term care after Anti-GBM disease for informational purposes only and does not replace medical advice. Your nephrologist and transplant team can interpret your results and plan care.
Get notified when new evidence is published on anti-basement membrane glomerulonephritis.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.